

Stroke Prevention – Medical and Lifestyle Measures

Hakan Sarikaya^a Jose Ferro^b Marcel Arnold^a

^aNeurology Department, University Hospital Bern, Bern, Switzerland; ^bDepartment of Neurosciences (Neurology), Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal

Key Words

Cerebrovascular disease · Hypertension · Ischemic stroke · Risk factors for stroke · Stroke · Prevention

Abstract

Background: According to the World Health Organization, stroke is the ‘incoming epidemic of the 21st century’. In light of recent data suggesting that 85% of all strokes may be preventable, strategies for prevention are moving to the forefront in stroke management. **Summary:** This review discusses the risk factors and provides evidence on the effective medical interventions and lifestyle modifications for optimal stroke prevention. **Key Messages:** Stroke risk can be substantially reduced using the medical measures that have been proven in many randomized trials, in combination with effective lifestyle modifications. The global modification of health and lifestyle is more beneficial than the treatment of individual risk factors. **Clinical Implications:** Hypertension is the most important modifiable risk factor for stroke. Efficacious reduction of blood pressure is essential for stroke prevention, even more so than the choice of antihypertensive drugs. Indications for the use of antihypertensive drugs depend on blood pressure values and vascular risk profile; thus, treatment should be initiated earlier in patients with diabe-

tes mellitus or in those with a high vascular risk profile. Treatment of dyslipidemia with statins, anticoagulation therapy in atrial fibrillation, and carotid endarterectomy in symptomatic high-grade carotid stenosis are also effective for stroke prevention. Lifestyle factors that have been proven to reduce stroke risk include reducing salt, eliminating smoking, performing regular physical activity, and maintaining a normal body weight.

© 2015 S. Karger AG, Basel

Introduction

Stroke is one of the most common causes of death and is the main cause of persistent and acquired disability in adults worldwide. Considering demographic changes, a further increase in stroke rates is expected. Moreover, stroke is expected to increasingly affect younger patients. The World Health Organization refers to stroke as the incoming epidemic of the 21st century. Therefore, currently, strategies for stroke prevention are of prime importance, particularly with regard to the recent studies suggesting that 85% of all strokes may be preventable [1]. Lifestyle modification is of particular interest for stroke prevention, as the incidence of stroke has decreased by up

Table 1. Evidence for recommendations on the treatment and lifestyle factors related to stroke

	Randomized trials	Observational studies
Arterial hypertension	×	
Diabetes mellitus	×	
Dyslipidemia	×	
Antithrombotics	×	
Atrial fibrillation	×	
Carotid stenosis	×	
Vitamin supplementation	×	
Dietary recommendations		×
Smoking		×
Physical activity		×
Alcohol		×
Overweight		×

to 42% in developed countries within the last 30 years, whereas an increase by more than 100% has been reported in developing countries [2]. This observation indicates the important role of lifestyle and diet; the prevalence of risk factors such as smoking, hyperlipidemia, or high blood pressure has decreased considerably, thereby increasing awareness among the populations of high-income countries. However, in low-income countries, industrialization has led to unfavorable food and lifestyle changes [2]. This review aims to discuss effective lifestyle modifications and medical interventions for optimal stroke prevention. An overview of the evidence for the recommendations is shown in table 1.

Medical Measures

Arterial Hypertension

Hypertension is the most important and modifiable risk factor for stroke. Uncontrolled hypertension is also a main cause of cognitive deficits and dementia. A reduction of systolic blood pressure (SBP) by 2 mm Hg was associated with stroke reduction by 25%, while reduction in diastolic blood pressure (DBP) led to stroke reduction by 50% [3]. The relationship between blood pressure and stroke risk is linear and continuous as the reduction of borderline hypertension (SBP 130–140 mm Hg and DBP 85–89 mm Hg) was also associated with risk reduction of stroke. Treatment of isolated SBP in elderly patients is also preventive: reduction of SBP >160 mm Hg to 145 mm Hg in patients aged >80 years was associated with stroke reduction by 30% within 2 years [4].

Efficacious reduction of blood pressure is much more important and essential for stroke prevention than the choice of antihypertensive drugs. The selection of drug class should be made based on comorbidities. Some studies and meta-analyses suggest a beneficial trend in favor of calcium antagonists and angiotensin-converting enzyme blockers [5], whereas beta blockers in hypertensive patients without heart disease seem to be less protective for stroke prevention. Recent studies indicate that a high variability in blood pressure is associated with a higher stroke risk, which again supports treatment with calcium antagonists [6]. Furthermore, patients with metabolic risk factors who are treated with thiazide diuretics or beta blockers seem to have a higher risk for the new onset of diabetes mellitus [7].

Indications for the use of antihypertensive drugs depend on blood pressure values and the vascular risk profile; thus, treatment should be initiated earlier in patients with diabetes mellitus or in those with a high vascular risk profile. In patients with a low risk profile and borderline blood pressure values, non-pharmaceutical treatment options should be used (e.g., low-salt diet, physical activity, or weight reduction). Antihypertensive drug treatment is recommended for all patients with blood pressure >140/90 mm Hg, whereas the treatment goal in high-risk patients should be ideally blood pressure levels of <130/80 mm Hg.

Dyslipidemia and Statins

The association between stroke and hypercholesterinemia is less clear, although it is an established risk factor for myocardial infarction. Many studies indicate an increased risk of ischemic stroke with higher serum cholesterol levels (>7 mmol/l), whereas lower cholesterol levels in patients with hypertension (SBP >145 mm Hg) tend to be associated with hemorrhagic stroke. Hypercholesterinemia is clearly related to carotid atherosclerosis [8], whereas HDL-cholesterol is inversely associated with the risk of ischemic stroke. Statins have been shown to prevent stroke markedly in patients with coronary heart disease, diabetes mellitus, or carotid stenosis, whereas this was not the case for the use of fibrates. The action of statins is assumed to be mediated through pleiotropic effects (anti-inflammatory, immunomodulatory, plaque stabilizer, vasodilatation) [9]. While the use of statins is clearly indicated for secondary prevention after ischemic stroke due to artery atherosclerosis, it is controversial whether statins may reduce stroke risk in the healthy population without vascular disease [10]. The absolute risk reduction for

healthy people seems to be rather low (0.2% per year), and so the use of statins in general cannot be recommended.

Diabetes Mellitus

Patients with diabetes mellitus have a higher risk of vascular events. According to a prospective observational study, patients with type 2 diabetes suffered more frequently from stroke than from myocardial infarction [11]. Diabetes promotes cerebral microangiopathy and causes lacunar type strokes. Current data indicate that metformin may be beneficial for stroke prevention in diabetes [12]. Intense control of hyperglycemia rather reduces microvascular complications, whereas the effect on macrovascular complications such as stroke is not clear [13]. Moreover, intense control of present vascular risk factors such as hypertension or dyslipidemia has been shown to efficiently reduce the risk of cardiovascular events in diabetic patients [14]. In addition, the use of statins has been shown to significantly reduce stroke risk (by 21% for each 1 mmol/l decrease in LDL-cholesterol).

Carotid Stenosis

The prevalence of asymptomatic carotid stenosis >50% increases with age and in patients with coronary heart disease, smoking, and diabetes mellitus. On the other hand, patients with carotid stenosis have a 4-fold higher risk of myocardial infarction than stroke [15]. While endarterectomy of symptomatic carotid stenosis is a proven and beneficial treatment for secondary stroke prevention, its value for asymptomatic stenosis remains controversial. Randomized trials from the nineties have suggested a benefit for surgery in asymptomatic carotid stenosis of ≥60% to ≥70% (relative risk reduction by 50%), provided the perioperative complication risk is less than 3% and patients have a life expectancy ≥5 years [16, 17]. Considering the absolute risk reduction of 1% per year, however, the treatment effect was rather low. Moreover, recent studies suggested a stroke risk of <1% per year for patients with asymptomatic carotid stenosis and treated with intensive medical therapy, which was primarily attributed to regular use of antihypertensive drugs and statins and lifestyle modification. This new observation questions the value of surgery in asymptomatic patients [18]. Therefore, current randomized studies such as SPACE-2 are investigating the absolute benefit of asymptomatic carotid stenosis. Percutaneous intervention by stenting is considered a justifiable alternative to surgery in symptomatic carotid stenosis, especially in patients younger than 70

years. Considering asymptomatic stenosis, the current body of evidence is insufficient for recommending stents as standard therapy.

Intracranial Stenosis

Current data recommend an aggressive medical treatment of intracranial stenosis as angioplasty and stenting in symptomatic patients was clearly associated with a higher risk of adverse outcomes [19]. Anticoagulation caused higher rates of intracranial hemorrhages than antiplatelet agents and was not superior in preventing a secondary ischemic stroke [20].

Atrial Fibrillation

The prevalence of atrial fibrillation increases with age (1% in 60-year-old patients, 18% in patients aged >85 years). It is the leading cause of stroke in the elderly and is associated with large infarcts and high mortality rates. A regular pulse palpation in patients aged >65 years and electrocardiography in the case of arrhythmic heart rate is recommended by cardiology societies to detect atrial fibrillation and prevent ischemic stroke [21]. The decision for anticoagulation in non-valvular atrial fibrillation is made according to the CHA₂ DS₂-VASc score [21]. As compared to the former CHADS₂-score, the new score places more emphasis on age, gender, and vascular co-morbidities of patients and recommends anticoagulation at a score ≥1 points, except for women without any other risk factors. Furthermore, the specificity in defining low-risk patients has also increased; thus, no more aspirin is recommended for this group (score = 0 points). In general, aspirin is less effective for stroke prevention in atrial fibrillation. Anticoagulation reduces the stroke risk by 70% in atrial fibrillation and the benefit of treatment in older patients with atrial fibrillation by far outweighs the bleeding risk, which can be estimated by HAS-BLED Score [22, 23]. However, studies indicate an underuse of anticoagulants due to physicians' perception on the risk of major bleeding as excessively high, because of the presence of clinical risk factors such as falls. It has been calculated that the risk of subdural hematoma that happens as a result of falling is so small that persons with an average stroke risk of 5% per year must fall approximately 300 times in a year for the risks of anticoagulation to outweigh its benefits [24]. As compared to vitamin K-antagonists, the new anticoagulants (thrombin inhibitor, factor Xa-antagonist) have the main advantages of easier usage and a higher safety profile, particularly a lower risk of intracranial hemorrhage. On the other hand,

the new oral anticoagulants may have the following disadvantages as compared with vitamin K-antagonists: short duration of action leading to increased stroke risk in case of poor compliance, lack of monitoring and antidote in case of emergent surgery or bleeding, and higher costs.

Patent Foramen Ovale

The best treatment for patent foramen ovale (PFO) in cryptogenic stroke is still under debate. Closure of PFO with Amplatzer devices seems reasonable in younger patients without vascular risk factors, whereas PFO in older stroke patients with vascular comorbidities is probably incidental and thus do not necessarily need a closure [25, 26]. The best medical treatment for PFO (antiplatelet vs. anticoagulant) is the subject of ongoing studies.

Sleep Disordered Breathing

Sleep disordered breathing (SDB) has been increasingly recognized as an independent risk factor for stroke [27, 28]. SDB can be the cause and the consequence of stroke [29, 30]. The high frequency (50–70%) of SDB in stroke patients, often in the form of obstructive sleep apnea (OSA), justifies the routine implementation of screening tools such as respiratory polygraph or apnea check. In severe OSA, treatment with continuous positive airway pressure (CPAP) may reduce the cardiovascular morbidity and mortality, whereas the evidence for efficient stroke prevention is still limited [31, 32].

Antithrombotics

For primary stroke prevention, acetylsalicylic acid (aspirin) has been the most investigated antithrombotic drug. The Women's Health Study reported a stroke reduction by 17% in healthy women taking 100 mg aspirin every 2 days as compared to placebo; however, the difference was statistically non significant [33]. In the Physicians' Health Study, no stroke prevention was observed in men treated with aspirin [34]. A recent meta-analysis including 95,000 participants found no association between aspirin and primary stroke prevention, in either women or men, whereas the rates of gastrointestinal bleeding were significantly increased in the aspirin arm [35]. Current data do not support a general use of aspirin for stroke prevention in the healthy population or in patients with diabetes mellitus [36]. On the other hand, antithrombotics including aspirin, clopidogrel, and dipyridamol are clearly indicated for secondary stroke prevention in patients with ischemic stroke (relative risk reduction by 20–25%).

Lifestyle Modification

Salt

The average salt intake in most Western countries is close to 10 g a day (and much higher in many Eastern European and Asian countries), whereas international recommendations suggest that average population salt intake should be less than 5–6 g per day [37]. Intake of higher salt amounts is associated with higher risk for ischemic and hemorrhagic stroke [37]. About 20% of all intracerebral hemorrhages are assumed to result from adding salt to food [38]. Moreover, reduction of dietary salt intake by half a teaspoon was associated with a reduction of cardiovascular events by 20% [39]. The risk is assumed to result from increased blood pressure, leading to fibrosis in the arteries, kidneys, and heart [40]. Reduction of dietary salt intake by a teaspoon (equal to 5–6 g salt) has been shown to reduce systolic and diastolic blood pressure by 7 and 4 mm Hg, respectively, in hypertensive patients, whereas blood pressure reduction in patients with resistant hypertension was much higher (systolic by 23 mm Hg and diastolic by 9 mm Hg, respectively) [41, 42]. Of note, many people consume prepared foods, which contain a lot of salt and this makes control of salt intake difficult.

Smoking

Cigarette smoking is an independent risk factor for stroke and potentiates the effect of other risk factors such as hypertension or hormone replacement therapy. The mechanism is due to reduced endogenous fibrinolysis and increased thrombocyte activity. Recent studies also suggest an association between passive smoking and stroke. Stroke risk was reduced by 50% one year after quitting smoking, and was comparable to that of non-smokers 5 years later.

Physical Activity

Regular physical activity decreases stroke risk by 25–30% through favorable effects on other vascular risk factors such as hypertension, hyperlipidemia, and overweight. The dose-effect relation is controversial, however; thus, it is not clear whether maximal physical activity leads also to maximal stroke reduction.

Overweight

Each unit increase in body mass index (BMI) has been suggested to increase stroke risk by 5%. However, stroke mortality is also increased in underweight patients. Markers of abdominal obesity such as waist-to-hip ratio or

waist circumference are reported to correlate better with stroke risk. While obesity is an established risk factor for stroke occurrence, recent studies report decreased mortality risk in obese stroke patients as compared to normal weight patients ('obesity paradox'). To date, however, randomized trials on risk modification by weight reduction are lacking.

Alcohol

The association between alcohol consumption and stroke risk is J-shaped: while slight to moderate alcohol intake (≤ 2 drinks per day for men and ≤ 1 drink per day for women, respectively) may reduce stroke risk by 30%, higher consumption significantly increases the risk of stroke.

Vitamins

There is robust evidence from many randomized trials that supplementation with vitamins A, C, E, or beta-carotene does not reduce the risk of stroke. Moreover, increased mortality rates have been observed for regular substitution with beta-carotene and vitamins A and E. Although hyperhomocysteinemia is a known risk factor for stroke and serum levels of homocysteine can be lowered by treatment with folic acid and vitamin B12, randomized trials did not prove stroke prevention by regular folate supplementation [43]. Vitamin B3 (niacin) was reported to reduce stroke risk in former studies, while statins were not used regularly. Supplementation with niacin increased HDL-cholesterol levels in patients treated with statins, but did not reduce stroke rates [44].

Potassium

Several observational studies and a meta-analysis have indicated that a higher potassium intake is associated with a reduction of stroke risk by 21% (relative risk 0.79, 95% CI 0.60–0.90) [45]. The effect seems to be dose-dependent: every increase in potassium intake by 1 g per day resulted in a reduction of stroke risk by 11% [46]. The mechanism is probably partially mediated by the reduction of blood pressure [47].

Calcium

Randomized trials have shown that calcium supplementation of >500 mg per day was associated with a significant risk for myocardial infarction and a trend toward an increase in stroke [48]. A meta-analysis of 3 placebo-controlled trials including $>20,000$ patients showed similar results for the combined supplementation of calcium and vitamin D [49].

Fats

Current studies indicate no significant association between stroke risk and the amount of fat intake, fat origin (animal vs. vegetable), and types of fats (saturated vs. polyunsaturated) [50, 51]. Consumption of industrially produced trans fats or saturated fatty acids, however, have been shown to increase the risk of coronary heart disease [52, 53]. Although marine-derived, omega-3 polyunsaturated fatty acids (from oily fish such as salmon or herring) have been reported to significantly reduce the risk of cardiovascular deaths in several randomized trials, no significant effect on stroke prevention has been demonstrated to date [54, 55]. On the other hand, the consumption of plant-derived omega-3 polyunsaturated fatty acids (from vegetable oils such as walnut, flaxseed, or soybean) has been reported to decrease stroke risk according to an observational study, although this needs to be confirmed in randomized trials [56].

Protein and Carbohydrates

The amount of protein intake and protein type (animal vs. vegetable) does not seem to be a risk factor for stroke [57]. Consumption of foods and liquids with added sugars and high dietary glycemic indices increases the risk for overweight, diabetes mellitus, and coronary heart disease [58]. Increased stroke mortality was reported among the Japanese people with high carbohydrate intake [59].

Foods and Beverages

Regular fish consumption was associated with a reduced stroke risk as reported by several observational studies [60], whereas daily meat consumption is shown to increase the risk of stroke [61]. Increased intake of fruits and vegetables (>5 servings per day) significantly reduce the stroke risk, whereas vegetable intake alone did not prevent strokes [1, 62]. The mechanism is not clearly known, although reduction of blood pressure is thought to play an important role. A recent study reported that high plasma levels of lycopene (e.g., found in tomatoes) were associated with a reduced risk of stroke by 50% [63]. Moderate consumption (3–4 cups) of coffee or tea has been shown to reduce stroke risk as compared with no consumption [64, 65]. The mechanism may be due to their antioxidative effects and improved endothelial function. Chocolate consumption was also associated with lower rate of stroke and cardiovascular disease, possibly mediated by the antiinflammatory and antithrombotic effects of cocoa [66]. Finally, the Mediterranean diet has recently been reported to reduce stroke risk [67].

Global Lifestyle Modification

Global modification of lifestyle has been shown to be more beneficial than the treatment of single risk factors. Patients fulfilling all 5 criteria of low-risk lifestyle (no smoking, regular physical activity ≥ 30 min per day, healthy nutrition, moderate alcohol consumption, BMI < 25 kg/m²) had a reduced stroke risk by 80% as compared to patients fulfilling none of these criteria [68].

Conclusions

In summary, stroke risk can be substantially reduced using the medical measures proven in many randomized trials. Arterial hypertension is by far the most important risk factor for stroke, whereas treatment of dyslipidemia with statins will further reduce the stroke risk. Anticoagulation in atrial fibrillation and carotid endarterectomy in symptomatic high-grade carotid stenosis are also very efficient in stroke prevention, whereas the general use of

aspirin, statins, or vitamins cannot be recommended for healthy people. Observational data strongly indicate that lifestyle modifications such as healthy diet, cessation of smoking and alcohol overuse, regular physical activity and achievement of normal body weight are beneficial for stroke prevention. However, one should consider that most lifestyle recommendations rely on case-control and epidemiological studies, which may be hampered by bias. The main challenge will be to educate and convince the population on the benefits that can be expected from healthy lifestyle and nutrition, as smoking and some dietary habits may rather be considered addictions. Therefore, structured therapy programs may be warranted in many situations.

Acknowledgment

The authors thank Turgut Tatlisumak (MD, PhD) for his valuable comments on the manuscript.

References

- 1 O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, et al: Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;376:112–123.
- 2 Hankey GJ: Nutrition and the risk of stroke. *Lancet Neurol* 2012;11:66–81.
- 3 Sokol SI, Kapoor JR, Foody JM: Blood pressure reduction in the primary and secondary prevention of stroke. *Curr Vasc Pharmacol* 2006;4:155–160.
- 4 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, et al: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 2008;358:1887–1898.
- 5 Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. *JAMA* 2003;289:2534–2544.
- 6 Rothwell PM: Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet* 2010;375:938–948.
- 7 Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. *Lancet* 2007;369:201–207.
- 8 Wilson PW, Hoeg JM, D'Agostino RB, Silbershatz H, Belanger AM, Poehlmann H, O'Leary D, Wolf PA: Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. *N Engl J Med* 1997;337:516–522.
- 9 Endres M: Statins and stroke. *J Cereb Blood Flow Metab* 2005;25:1093–1110.
- 10 Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359:2195–2207.
- 11 Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H: Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). *Exp Clin Endocrinol Diabetes* 2007;115:495–501.
- 12 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:854–865.
- 13 Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, et al: Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med* 2011;364:818–828.
- 14 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383–393.
- 15 Goessens BM, Visseren FL, Kappelle LJ, Algra A, van der Graaf Y: Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. *Stroke* 2007;38:1470–1475.
- 16 Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA* 1995;273:1421–1428.
- 17 Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D: Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet* 2004;363:1491–1502.
- 18 Abbott AL: Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. *Stroke* 2009;40:e573–e583.
- 19 Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. *N Engl J Med* 2011;365:993–1003.
- 20 Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, et al: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *N Engl J Med* 2005;352:1305–1316.

- 21 Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, et al: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;31:2369–2429.
- 22 Pisters R, Lane DA, Nieuwlaar R, de Vos CB, Crijns HJ, Lip GY: A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138:1093–1100.
- 23 Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999;131:492–501.
- 24 Man-Son-Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. *Arch Intern Med* 1999;159:677–685.
- 25 Stortecky S, da Costa BR, Mattle HP, Carroll J, Hornung M, Sievert H, Trelle S, Windecker S, Meier B, Juni P: Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. *Eur Heart J* 2014;pii:ehu292, Epub ahead of print.
- 26 Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, et al: An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. *Neurology* 2013;81:619–625.
- 27 Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V: Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med* 2005;353:2034–2041.
- 28 Bradley TD, Floras JS: Obstructive sleep apnoea and its cardiovascular consequences. *Lancet* 2009;373:82–93.
- 29 Bassetti CL, Milanova M, Gugger M: Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. *Stroke* 2006;37:967–972.
- 30 Hermann DM, Bassetti CL: Sleep-related breathing and sleep-wake disturbances in ischemic stroke. *Neurology* 2009;73:1313–1322.
- 31 Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM: Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. *Ann Intern Med* 2012;156:115–122.
- 32 Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, Martinez-Alonso M, Carmona C, Barcelo A, Chiner E, Masa JF, Gonzalez M, Marin JM, et al: Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA* 2012;307:2161–2168.
- 33 Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005;352:1293–1304.
- 34 Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. *N Engl J Med* 1989;321:129–135.
- 35 Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, et al: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009;373:1849–1860.
- 36 De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, Nicolucci A: Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. *BMJ* 2009;339:b4531.
- 37 Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP: Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ* 2009;339:b4567.
- 38 Jamrozik K, Broadhurst RJ, Anderson CS, Stewart-Wynne EG: The role of lifestyle factors in the etiology of stroke. A population-based case-control study in Perth, Western Australia. *Stroke* 1994;25:51–59.
- 39 He FJ, MacGregor GA: Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. *Lancet* 2011;378:380–382.
- 40 Frohlich ED: The salt conundrum: a hypothesis. *Hypertension* 2007;50:161–166.
- 41 He FJ, MacGregor GA: Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens* 2002;16:761–770.
- 42 Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA: Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension* 2009;54:475–481.
- 43 Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bona KH, Spence JD, Nygard O, Jamson R, et al: Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. *Arch Intern Med* 2010;170:1622–1631.
- 44 Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011;365:2255–2267.
- 45 D'Elia L, Barba G, Cappuccio FP, Strazzullo P: Potassium intake, stroke, and cardiovascular disease: a meta-analysis of prospective studies. *J Am Coll Cardiol* 2011;57:1210–1219.
- 46 Larsson SC, Orsini N, Wolk A: Dietary potassium intake and risk of stroke: a dose-response meta-analysis of prospective studies. *Stroke* 2011;42:2746–2750.
- 47 Dickinson HO, Nicolson DJ, Campbell F, Beyer FR, Mason J: Potassium supplementation for the management of primary hypertension in adults. *Cochrane Database Syst Rev* 2006;CD004641.
- 48 Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 2010;341:c3691.
- 49 Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR: Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. *BMJ* 2011;342:d2040.
- 50 He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, Ascherio A: Dietary fat intake and risk of stroke in male US healthcare professionals: 14 year prospective cohort study. *BMJ* 2003;327:777–782.
- 51 Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, et al: Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA* 2006;295:655–666.
- 52 Mozaffarian D, Aro A, Willett WC: Health effects of trans-fatty acids: experimental and observational evidence. *Eur J Clin Nutr* 2009;63(suppl 2):S5–S21.
- 53 Mozaffarian D, Micha R, Wallace S: Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2010;7:e1000252.
- 54 Marik PE, Varon J: Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. *Clin Cardiol* 2009;32:365–372.
- 55 Galan P, Kesse-Guyot E, Czernichow S, Briancan S, Blacher J, Hercberg S: Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. *BMJ* 2010;341:c6273.
- 56 de Goede J, Verschuren WM, Boer JM, Kromhout D, Geleijnse JM: Alpha-linolenic acid intake and 10-year incidence of coronary heart disease and stroke in 20,000 middle-aged men and women in the Netherlands. *PLoS One* 2011;6:e17967.
- 57 Preis SR, Stampfer MJ, Spiegelman D, Willett WC, Rimm EB: Lack of association between dietary protein intake and risk of stroke among middle-aged men. *Am J Clin Nutr* 2010;91:39–45.
- 58 Livesey G, Taylor R, Hulshof T, Howlett J: Glycemic response and health – a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. *Am J Clin Nutr* 2008;87:258S–268S.

- 59 Oba S, Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Shimizu H: Dietary glyce-mic index, glycemic load, and intake of carbo-hydrate and rice in relation to risk of mortal-ity from stroke and its subtypes in Japanese men and women. *Metabolism* 2010;59:1574–1582.
- 60 Larsson SC, Orsini N: Fish consumption and the risk of stroke: a dose-response meta-anal-ysis. *Stroke* 2011;42:3621–3623.
- 61 Micha R, Wallace SK, Mozaffarian D: Red and processed meat consumption and risk of inci-dent coronary heart disease, stroke, and dia-betes mellitus: a systematic review and meta-analysis. *Circulation* 2010;121:2271–2283.
- 62 He FJ, Nowson CA, MacGregor GA: Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. *Lancet* 2006;367:320–326.
- 63 Karppi J, Laukkanen JA, Sivenius J, Ronkain-en K, Kurl S: Serum lycopene decreases the risk of stroke in men: a population-based fol-low-up study. *Neurology* 2012;79:1540–1547.
- 64 Larsson SC, Orsini N: Coffee consumption and risk of stroke: a dose-response meta-anal-ysis of prospective studies. *Am J Epidemiol* 2011;174:993–1001.
- 65 Arab L, Liu W, Elashoff D: Green and black tea consumption and risk of stroke: a meta-analysis. *Stroke* 2009;40:1786–1792.
- 66 Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di Angelantonio E, Franco OH: Chocolate consumption and car-diometabolic disorders: systematic review and meta-analysis. *BMJ* 2011;343:d4488.
- 67 Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, et al: Primary preven-tion of cardiovascular disease with a Medi-terranean diet. *N Engl J Med* 2013;368:1279–1290.
- 68 Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB: Primary prevention of stroke by healthy lifestyle. *Cir-culation* 2008;118:947–954.